Fernand Labrie

This inventor holds 97 USPTO granted patents and 9 published patent applications, plus 12 CIPO patents and 12 EPO patents, primarily in Sex Steroid Precursors (CPC class 514177). Top assignees: Endorecherche, Inc., Roussel Uclaf, Endoreoherche, Inc.. Active years: 1984-2023.

USPTO Granted Patents = 97 (Patent Applications = 9)

% Patents Active = 89.7

CIPO Patents = 12 (Patent Applications = 4)

EPO Patents = 12 (Patent Applications = 13)

Average Co-Inventor Count = 1.4

ph-index = 22

Forward Citations = 1,605(Granted Patents)

Forward Citations (Not Self Cited) = 1,245(Dec 10, 2025)

Inventors with similar research interests:

Location History:

Ste.-Foy, CA (1996)
Ste-Foy, CA (1993 - 2002)
Sainte-foy, CA (2002 - 2015)
de la Promenade, CA (2016)
Quebec, CA (1984 - 2021)
Québec, CA (2010 - 2023)

Company Filing History:

6. 9 out of 834,411

Other

patents

where one patent can have more than one assignee

Years Active: 1984-2023

Loading Chart...

Areas of Expertise:

Breast Cancer

Cognition Loss

Alzheimer's Disease

Sexual Dysfunction

Androgen Deficiency

Pharmaceutical Compositions

Selective Estrogen Receptor Modulators

Insulin Resistance

Vaginal Dryness

Antiandrogens

Combination Therapy

Hormone Therapy

97 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 11690852 - Reduction of the incidence or recurrence of breast cancer in postmenopausal women treated with intravaginal sex steroid precursor (2023-07-04),

2. 11576891 - Methods of treating or preventing estrogen-related diseases (2023-02-14),

3. 11452731 - Method of treating and preventing loss of cognition (2022-09-27),

4. 10881650 - Pharmaceutical compositions (2021-01-05),

5. 10548903 - Treatment of male androgen deficiency symptoms or diseases with sex steroid precursor combined with SERM (2020-02-04),

6. 10478443 - Sex steroid precursors alone or in combination with selective estrogen receptor modulators for the prevention and treatment of sexual dysfunction in postmenopausal women (2019-11-19),

7. 10342805 - Treatment of Alzheimer's disease, loss of cognition, memory loss and dementia with sex steroid precursors in combination with selective estrogen receptor modulators (2019-07-09),

8. 10076525 - Sex steroid precursors alone or in combination with selective estrogen receptor modulators for the prevention and treatment of dyspareunia in postmenopausal women (2018-09-18),

9. 9744177 - Treatment of male androgen deficiency symptoms or diseases with sex steroid precursor combined with SERM (2017-08-29),

10. 9682960 - Non-steroidal antiandrogens and selective androgen receptor modulators with a pyridyl moiety (2017-06-20),

11. 9284345 - 17alpha-substituted steroids as systemic antiandrogens and selective androgen receptor modulators (2016-03-15),

12. 9090651 - Helix 12 directed pharmaceutical products (2015-07-28),

13. 8957054 - Pharmaceutical compositions (2015-02-17),

14. 8835413 - Sex steroid precursors alone or in combination with a selective estrogen receptor modulator and/or with estrogens and/or a type 5 cGMP phosphodiesterase inhibitor for the prevention and treatment of vaginal dryness and sexual dysfunction in postmenopausal women (2014-09-16),

15. 8629129 - Pharmaceutical compositions (2014-01-14),

Sure, here is the article on inventor Fernand Labrie:

Title: Innovator Spotlight: Fernand Labrie - Pioneering Breakthroughs in Women's Health

Introduction:

Fernand Labrie, a distinguished inventor hailing from Quebec, CA, has made remarkable contributions to the field of women's health with his groundbreaking innovations. With an impressive portfolio of 97 patents under his name, Labrie has been at the forefront of developing novel therapies to improve the lives of postmenopausal women worldwide.

Latest Patents:

Labrie's recent patents focus on revolutionizing the treatment and prevention of breast cancer and estrogen-related diseases in postmenopausal women. One of his notable inventions includes the intravaginal use of sex steroid precursor, such as DHEA, to reduce the incidence or recurrence of breast cancer. Additionally, his innovative methods for treating estrogen-related diseases by administering selective estrogen receptor modulators have paved the way for more effective therapies in women's health.

Career Highlights:

Throughout his illustrious career, Fernand Labrie has held key positions at reputable companies such as Endorecherche, Inc. and Roussel Uclaf. His unwavering dedication to advancing women's health has garnered him international recognition as a leading expert in hormone therapies and related fields.

Collaborations:

Labrie's impactful work wouldn't have been possible without the collaboration of esteemed colleagues like Yves M Merand and Jean-Pierre Raynaud. Together, they have synergized their expertise to drive innovation and shape the future of women's health treatments.

Conclusion:

In conclusion, Fernand Labrie stands as a shining example of a visionary inventor who has significantly influenced the landscape of women's health through his pioneering research and patent portfolio. His relentless pursuit of excellence and commitment to improving healthcare outcomes continue to inspire future generations of inventors and researchers in the field.